INTRODUCTION
There is growing clinical and scientific evidence to support the concept of Pediatric Acute Neuropsychiatric Syndrome (PANS) in children undergoing assessment, diagnosis, and treatment of sudden onset obsessive-compulsive disorder (OCD) or severely restricted food intake . Proposed diagnostic criteria for PANS are as follows: 1) sudden onset (<72 hours) of OCD or eating restriction; 2) at least two qualifying attributes (anxiety; mood or behavior disturbances; irritability or aggression; developmental regression; deterioration in school performance; sensory or motor abnormalities; and somatic symptoms); and 3) lack of a known medical or neurologic disorder to better explain symptoms (Swedo et al., 2012) .
Use of the term PANS has evolved from literature on Pediatric Autoimmune
Neuropsychiatric Disorders Associated with Streptococcal infections (PANDAS; Swedo et al., 1998) . PANDAS is proposed to have a pathophysiology similar to that of Sydenham's chorea, which in turn is a neurological manifestation of rheumatic fever -an autoimmune disease triggered by streptococcal infections (Swedo, 1994 , Swedo et al., 1998 . The PANDAS criteria are similar to the PANS criteria, but include tics or tic-disorder as a possible primary symptom, and require a confirmed streptococcal infection before symptom onset. The requirement of a streptococcal infection may be too narrow a criterion for effective clinical use, and hence the later defined term PANS requires no specific infection for diagnosis (Swedo et al., 2012) . See table 1 for PANS and PANDAS criteria used in this study.
The suggested autoimmune etiology of the conditions has led to suggestion of alternative treatment options (Chang et al., 2015) , and the development of possible diagnostic biomarkers. Autoantibodies to dopamine receptors D1 and D2, β-tubulin, and lysoganglioside-GM1 (lyso-GM1) and calcium calmodulin dependent kinase II activity (CaMKII-activity) previously linked to Sydenham's chorea are proposed biomarkers for PANDAS and acute-onset OCD (Cox et al., 2013 , Kirvan et al., 2003 , Kirvan et al., 2006 , Kirvan et al., 2007 , Singer et al., 2015 . The above are analytes of the Cunningham Panel (Moleculera, 2016) , a commercially available set of assays intended for diagnosing PANS or PANDAS and for monitoring symptom severity currently performed by Moleculera Labs, Oklahoma, City, OK, USA.
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CaMKII activity has been shown to be elevated by monoclonal antibodies from patients with Chorea, and in addition these antibodies bind to both Lysoganglioside and to an epitope in the GABHS cell wall, implying molecular mimicry as a cause for the autoimmune process (Kirvan et al., 2003) . This process has also been shown in serum from children with PANDAS, thus strengthening both the link between Sydenham's Chorea and PANDAS, as well as supporting the diagnostic use of these analytes (Kirvan et al., 2006) .
Despite multiple studies (Cox et al., 2013 , Cox et al., 2015 , Kirvan et al., 2006 , MorrisBerry et al., 2013 , Singer et al., 2008 , Singer et al., 2015 , it remains unclear whether these biomarkers are sensitive and specific markers of PANS or PANDAS. In previous studies of the Cunningham Panel, mean and median relationships in patient populations and comparison samples were analyzed, without addressing diagnostic accuracy (Cox et al., 2013 , Cox et al., 2015 , Kirvan et al., 2006 , Singer et al., 2015 . No association between symptom exacerbations and biomarker levels has been shown in prospective studies (Morris-Berry et al., 2013 , Singer et al., 2008 , Singer et al., 2015 ; and in a recent therapeutic trial involving children with PANDAS (Williams et al., 2016) , treatment response in both intervention and placebo groups was jointly predicted by CaMKII activation and antinuclear antibody (ANA) titers. Thus, the clinical utility of the Cunningham Panel is subject to question.
Objectives of this study were as follows: 1) evaluate the Cunningham Panel as a diagnostic tool for PANS and PANDAS, 2) determine if clinical improvement coincides with decreased CaMKII activity, and 3) compare Cunningham Panel results in patients who meet criteria for PANS or PANDAS with results from healthy controls.
METHOD 2.1 Study design
This study is a diagnostic accuracy study with the aim to evaluate the Cunningham Panel as a diagnostic tool for PANS and PANDAS. Reference standard for diagnosing PANS or PANDAS is a comprehensive psychiatric interview performed by an experienced physician (Chang et al., 2015) . The test evaluated in this study, i.e. the index test, is the Cunningham Panel (Moleculera, 2016) . The relationship between symptom severity changes and shifts in
Cunningham Panel results is also examined, test-retest reliability is investigated, and panel results in patients with PANS or PANDAS are compared with those of healthy controls. 
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Healthy controls
Twenty-seven healthy controls, age and gender-matched to study subjects, were recruited in August, 2016. Exclusion criteria for healthy controls were psychiatric care 1 year before inclusion and lifetime duration of any psychiatric, autoimmune, or movement disorder. Six of these participants did not provide a blood sample, resulting in 21 healthy control participants being included in the study. 
Blinding and study integrity
Diagnostic accuracy of Cunningham Panel
Reference standard of diagnosis: Psychiatric interview
The goal of the psychiatric interview was to make valid PANS and PANDAS diagnoses. 
Index test of diagnosis: Cunningham Panel of PANS biomarkers
The Cunningham Panel provides a measure of CaMKII activity and autoantibodies to dopamine receptors D1 and D2, β-tubulin, and lyso-GM1. ELISA assays of these autoantibodies are described comprehensively by Moleculera Labs (Moleculera, 2016) and are detailed elsewhere in the literature (Kirvan et al., 2007 , Singer et al., 2015 . Assay of serum CamKII activity is described by Kirvan et al. (2003) and Moleculera (2016) . In Sweden, serum obtained for a Cunningham Panel is first sent to Wieslab, where it is frozen. It is then forwarded to Moleculera to undergo standardized procedural analysis. Results are returned to Wieslab, and the referring physician receives a copy of the printed report.
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Cunningham Panel results relative to change in psychiatric health
Because CaMKII activity is suggested to be used for monitoring treatment outcome, we expected changes would follow severity of psychiatric symptoms. Given the one-time nature of interviews, the measure of change in psychiatric symptoms was done in retrospect, using self-or parent-rated Clinical Global Impression-Improvement (CGI-I) scores (Guy, 1976) .
Each participant or caretaker was asked: "Compared to when you took the first Cunningham Panel test, how do you feel today?" Mental health changes were ranked on a 7-point Likert scale, where 1 is "very much improved" and 7 is "very much worse". A rating of 4 represented no change in status. Caretakers' scores were primarily used, but if no caretaker score was available, the participant score was used. The CGI-I ratings and time point 2 blood samples were obtained a mean of 74 weeks after the initial sample at time point 1.
Test-retest reliability of Cunningham Panel
Ten participants who provided blood samples at time point 2 contributed to this arm of the study. A total of seven 4.5-ml tubes of whole blood were collected (at one sitting) from each subject. One serum sampling tube (BD Vacutainer, yellow top) was sent to Wieslab for CaMKII analysis at the time of sampling, and one identical serum tube was sent to a biobank at Karolinska Institutet, Stockholm, Sweden (KI Biobank) for serum separation and storage at -80° C. After a mean of 396 days in storage, 10 serum samples at KI Biobank were selected by one of the authors (EH) and sent to Wieslab for second, blinded analysis of CaMKII activity. Results of initial and subsequent CaMKII assays were compared. (antibody or CaMKII) positive. Sensitivity, specificity, predictive value, accuracy, and diagnostic odds ratio were calculated using cross tabulation for PANS and PANDAS separately. 
Data analysis and statistics
Cunningham Panel results relative to change in psychiatric health
Test-retest reliability of Cunningham Panel
All data are presented below and in supplementary table S1.
Comparison with healthy controls
Twenty-one healthy controls provided blood samples that were analyzed with the Cunningham Panel. Samples were sent to Wieslab for analysis according to standard procedure. For this analysis, we used the baseline test from time point 1, as the patient group result. CaMKII activity was considered normally distributed and was compared by t-test.
Titers of autoantibodies were not normally distributed, so Mann-Whitney U test was used for comparisons.
RESULTS
Participant characteristics and PANS and PANDAS status
Of the 53 participants, 40 were children and adolescents (ages 5-19, mean age 11.6 years) and 13 were adults (mean age 24.5 years). Twenty participants were female and 33 were male. Mean age of onset of severe psychiatric symptoms was 7.8 years. were non-significant, i.e. the 50% line was within the calculated confidence intervals of the Area under the curve. Area under the curve for Lyso-GM1 was 65.5% (95% CI 50.5% -80.6%). In contrast, the diagnostic odds ratio for Lyso-GM1 was >1 and it had an accuracy of 58%. See table 3 for details on diagnostic properties and supplementary table   S4 for cross-tabulation data.
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Diagnostic accuracy of Cunningham Panel in PANDAS
Diagnostic accuracy of Cunningham Panel in PANS
Cunningham Panel results relative to change in psychiatric health
Seven participants did not provide a second blood sample and 3 participants did not provide a CGI-I score, resulting in 43 patients being included in this analysis. There was a moderate correlation between difference in CaMKII and in CGI-I in patients who met diagnostic criteria for PANS or PANDAS (n=18 r=0.522; p=0.04), but not in the non-PANS or PANDAS group (n=25 r=-0. 263; p=0.20) . A scatterplot of the correlation is presented as supplementary figure S3 .
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Test-retest reliability of Cunningham Panel
In 2 out of 10 samples, the CaMKII-results were clinically different, i.e. on different sides of the diagnostic cutoff set by Moleculera, between the first and second analysis. A third sample differed more than two standard deviations between the two analyses. Seven of the 10 samples had small differences between the two analyses sampled on the same occasion. The second analysis results were both higher and lower than the first analysis results. Full results are presented in supplementary table S1. 
Cunningham Panel results and comparison to healthy controls
Reference standard of diagnosis: Psychiatric interview
The main limitation of our psychiatric assessment is that it relied on retrospective reports for diagnosis of PANS and PANDAS. Patients were seen in one single sitting, in most cases several years after the first psychiatric symptoms emerged. Preferably, the diagnostic workup should be done at symptom onset. However, psychiatric symptoms are often reported in retrospect, and most patients had ongoing symptoms during the psychiatric interview. The validity of our psychiatric interview is strengthened by the use of well validated instruments.
We also defined interview content and diagnostic criteria prior to study start and in accordance with PANS and PANDAS literature, which further strengthens the validity of the psychiatric interview.
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Sample size and recruitment
The sample size of this study is small, especially the size of the group meeting diagnostic criteria for PANDAS (n=13). Nevertheless, the sample is highly representative of the group of patients likely undergo clinical testing with the Cunningham Panel. Using the known proportion of positive and negative CaMKII results in the full Wieslab sample (73%), we have calculated that in order to reach a sensitivity of 90%, we would need to add 50 more participants, all classified correctly as cases by both reference-and index test. In such a hypothetical model, the specificity of CaMKII for diagnosing PANDAS would be 49%, meaning that half of the identified cases would be false positives. In the light of this, we argue that the sample size is large enough to conclude that the diagnostic accuracy of the Cunningham Panel is poor.
The sample size of the test-retest reliability sample is too small for a definite statistical analysis, which is a limitation. The cost of the Cunningham Panel did not allow us to reanalyze more than 10 samples. However, the finding that three of 10 results may be unreliable after storage in -80°C is surprising. In 2015 a study reporting longitudinal CaMKII activity data from 8 children with PANDAS, authored by researchers associated with Moleculera Labs, stated that "samples were collected aliquoted, frozen and stored" (Singer et al., 2015) . It is unclear for how long the samples were stored in the study, but the authors state that the sera was prospectively collected within a larger study, from which results were presented already in 2008 (Kurlan et al., 2008) . There in an expected variability in antibody levels in sera that has been frozen and thawed (Hendriks et al., 2014 ) and this should be taken into account when interpreting these results, as well as when conducting future studies.
The sample size of the healthy control group was also small. However, results were surprising, with 18 out of 21 of the healthy control samples having a pathological result on at least one of the analytes included in the Cunningham Panel, which indicates poor diagnostic accuracy even in this small sample. Our results indicate a similar variability as a previous study of the Cunningham Panel, which presented data from 4 independent healthy samples (Singer et al., 2015) . When interpreting our results, it should also be noted that the healthy controls were not tested for streptococcal infections.
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Changes in CaMKII values and correspondence to symptom severity
The analysis of change in CaMKII and change in symptoms suffer from several limitations. First, the time between the two CaMKII results differed between subjects and the expected fluctuation over time of CaMKII is unknown. Second, the use of the parent rated CGI-I is not an ideal measure of change in symptom severity. There is an obvious risk for recall bias influencing the results, and the measure is probably insensitive. By taking the time point 2 blood sample after the collection of CGI-I data, thereby blinding participants to change in CaMKII results, the risk of recall bias was possibly mitigated. Still, the results from this specific analysis should be interpreted with caution.
Serum sampling was not done in relation to symptom exacerbations in this study, and this may have caused an underestimation of Cunningham Panel correspondence to clinical exacerbations. However, a previous study using a design where samples were collected at clinical exacerbations presented no such association (Singer et al., 2015) .
Conclusions
Although our findings identified a moderate correlation between change in CaMKII and change in symptom severity in individuals with PANS or PANDAS, there was no indication that the Cunningham Panel can be used to diagnose PANS or PANDAS. Our results also suggest that test-retest reliability of CaMKII may be insufficient, and that Cunningham Panel results are commonly elevated in healthy controls.
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